RxDoctor Payments DataLook up a doctor →

Adarsh Jha, MD

Endocrinology, Diabetes & Metabolism · East Hartford, CTNPI 1710188685

Payments from drug & device makers

$22,132in general payments, 2019–2025

Across 1,078 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Abbott$2K
  • Lilly USA, LLC$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • plus $10K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)78$2,947
Abbott116$2,291
Lilly USA, LLC97$1,763
Boehringer Ingelheim75$1,469
AstraZeneca(2 entities)80$1,367
Novo Nordisk85$1,290
GSK58$1,250
Sanofi-aventis U.S. LLC59$1,074
Corcept Therapeutics32$729
AbbVie37$621
Dexcom, Inc.20$398
Mallinckrodt Hospital Products Inc.19$370
Amneal Pharmaceuticals LLC18$346
Takeda Pharmaceuticals U.S.A., Inc.13$334
Xeris Pharmaceuticals, Inc.20$330
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$302
Lifescan, Inc.17$275
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$253
Radius Health, Inc.11$247
Endo Pharmaceuticals Inc.15$241
Astellas Pharma US Inc9$218
Exact Sciences7$196
Neurocrine Biosciences, Inc.7$193
Johnson & Johnson14$182
Mannkind Corporation4$157
Bayer5$153
Merck9$141
Cequr Corporation3$137
Otsuka America Pharmaceutical, Inc.7$134
Novartis5$132
Actelion Pharmaceuticals US, Inc.5$115
IBSA Pharma Inc.6$110
Pfizer7$108
Madrigal Pharmaceuticals2$103
Harmony Biosciences LLC5$101
Tandem Diabetes Care, Inc.4$98
Amarin Pharma, Inc.5$97
Verona Pharma, Inc.4$87
Chiesi USA, Inc.4$82
Advanced Respiratory, Inc4$80
Almatica Pharma LLC4$73
Lexicon Pharmaceuticals, Inc.4$72
Soleno Therapeutics, Inc.2$72
Amryt Pharma Holdings Ltd4$72
Ultragenyx Pharmaceutical Inc.4$70
Ascendis Pharma Endocrinology Inc3$63
Arbor Pharmaceuticals, Inc.3$61
Alvogen Inc3$59
Kyowa Kirin, Inc.3$52
Antares Pharma, Inc.3$52
Recordati_rare_diseases_inc.2$48
BETA Bionics, Inc.2$48
Medtronic3$46
Amphastar Pharmaceuticals, Inc.2$46
Insulet Corporation3$43
Eisai Inc.3$41
Kowa Pharmaceuticals America, Inc.3$41
Vanda Pharmaceuticals Inc.1$40
Axsome Therapeutics, Inc.2$40
Shire North American Group Inc2$36

How this compares

$22,132 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024
$100,633
Medicare patients
307
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in East Hartford

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →